- Home
- SEVN vs PRQR Comparison
SEVN vs PRQR Comparison
Compare SEVN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | PRQR |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 190.5M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SEVN | PRQR |
|---|---|---|
| Price | $6.70 | $1.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $8.70 | $7.78 |
| AVG Volume (30 Days) | 175.7K | ★ 902.2K |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | ★ 16.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $15.13 | $8.25 |
| Revenue Next Year | $16.21 | N/A |
| P/E Ratio | $13.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $1.20 |
| 52 Week High | $9.81 | $2.49 |
Technical Indicators
Market Signals| Indicator | SEVN | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 40.65 |
| Support Level | $5.98 | $1.20 |
| Resistance Level | $7.05 | $1.54 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 64.21 | 41.67 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.